MGTX Projected Dividend Yield
Ord/MeiraGTx Holdings PLC ( NASDAQ : MGTX )MeiraGTx Holdings PLC is a clinical-stage gene therapy company focused on addressing unmet medical needs in ocular diseases, severe xerostomia, and neurodegenerative disorders. Its product pipeline features several innovative therapies, including botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa, AAV-hAQP1 for radiation-induced xerostomia and Sjögren's syndrome, and AAV-GAD for Parkinson's disease. Additionally, it develops treatments for inherited retinal dystrophies, such as AAV-RPE65 for RPE65-associated conditions and AAV-CNGB3 and AAV-CNGA3 for achromatopsia. MeiraGTx aims to advance gene therapies to enhance patient outcomes in these critical areas. 21 YEAR PERFORMANCE RESULTS |
MGTX Dividend History Detail MGTX Dividend News MGTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |